Phase 3 Study of Ublituximab in combination with Ibrutinib compared to Ibrutinib Alone in CLL pts.

Clinical Trial Grant

Duke Scholars

Principal Investigator Danielle Marie Brander Medicine, Hematologic Malignancies and Cellular Therapy

Administered By

Duke Cancer Institute

Awarded By

TG Therapeutics, Inc

Start Date

March 1, 2015

End Date

February 28, 2022

Administered By

Duke Cancer Institute

Awarded By

TG Therapeutics, Inc

Start Date

March 1, 2015

End Date

February 28, 2022